Researcher Profile

Researcher Profile

Nelson Shu-Sang Yee, MD, PhD, RPh

Nelson Shu-Sang Yee, MD, PhD, RPh

Associate Professor, Department of Medicine
Division of Hematology and Oncology
Assistant Professor, Department of Medicine
Scientific Program:Experimental Therapeutics
Disease Teams:
Gastrointestinal Cancer
Liver, Pancreas and Foregut Cancer

Research Interests

  • Therapeutics
  • Pancreatic Neoplasms
  • Neoplasms
  • Adenocarcinoma
  • Zebrafish
  • Ion Channels
  • Biomarkers
  • Pancreas
  • Mast Cells
  • Growth
  • Exocrine Pancreas
  • Mutation

Clinical Trials

MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
MATCH Treatment Subprotocol F: Crizotinib in Patients with Tumors (Other Than Adenocarcinoma of Lung or ALCL) with ALK Rearrangements
MATCH Treatment Subprotocol G: Phase II Study of Crizotinib in Patients with ROS1 Translocations (Other Than Patients with Non-Small Cell Lung Cancer)
MATCH Treatment Subprotocol L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
MATCH Treatment Subprotocol M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with c-Kit Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor).
Extracellular Vesicles as Biomarkers for Early Detection of Recurrent Pancreatic Carcinoma
CHARM II: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts: a prospective, randomized, double-blind, multi-center clinical trial
Risk Factors for CIPN Following an Oxaliplatin-Containing Chemotherapy Regimen in Colorectal Cancer Patients

Recent Publications


Merle, P, Blanc, JF, Phelip, JM, Pelletier, G, Bronowicki, JP, Touchefeu, Y, Pageaux, G, Gerolami, R, Habersetzer, F, Nguyen-Khac, E, Casadei-Gardini, A, Borbath, I, Tran, A, Wege, H, Saad, AS, Colombo, M, Abergel, A, Richou, C, Waked, I, Yee, NS-S, Molé, A, Attali, P, Le Boulicaut, J, Vasseur, B, Moussata, D, Grangé, JD, Ratziu, V, Khemissa-Akouz, F, Regnault, H, Dauvois, B, Zarski, JP, Ollivier-Hourmand, I, Manfredi, S, Debette-Gratien, M, Gangloff, A, Fontanges, T, Baron, A, Bouattour, M, Vincent, J, Sieghart, W, Maieron, A, Peeters, M, Delwaide, J, Lasser, L, Berg, T, Schultheiß, M, Zipprich, A, Trojan, J, Ehmer, U, Luppi, G, Luca, G, Tamberi, S, Amoroso, D, Alabiso, O, Buonadonna, A, Toniutto, P, Tamburini, E, Cubillo, A, Muñoz, A, Guillén, C, Sánchez, G, Manzano, H, Navarro, V, Ales, I, Massuti, B, Dank, M, Bodoky, G, Kahan, Z, Horváth, Z, Gabrail, N, Ozer, H, Galanopoulos, C, Hauke, R, Raj, M, Harputluoglu, H, Sevinc, A, Goker, E, Coker, A, Yalcin, S, Ali, M, Ata, O, Tugba, I, ElKassas, M, Abdel, A, Wakid, I, Shamaa, S, El, N, Kohail, H, Makarem, J, Chehade, I, Farhat, F, López, C & Marín, M 2019, 'Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial', The Lancet Gastroenterology and Hepatology, vol. 4, no. 6, pp. 454-465.
Wan, Y, Maurer, M, He, HZ, Xia, YQ, Hao, SJ, Zhang, WL, Yee, NS-S & Zheng, S 2019, 'Enrichment of extracellular vesicles with lipid nanoprobe functionalized nanostructured silica', Lab on a Chip, vol. 19, no. 14, pp. 2346-2355.
Yee, NS-S & Lee, NP 2019, 'Special issue: Cancer biomarkers and targets in digestive organs', Biomedicines, vol. 7, no. 1, 3.


Yee, NS-S, Lengerich, E, Schmitz, K, Maranki, J, Gusani, NJ, Tchelebi, L, Mackley, H, Krok, K, Baker, M, de Boer, C & Yee, JD 2018, 'Frontiers in gastrointestinal oncology: Advances in multi-disciplinary patient care', Biomedicines, vol. 6, no. 2, 64.
Fonkoua, LK & Yee, NS-S 2018, 'Molecular characterization of gastric carcinoma: Therapeutic implications for biomarkers and targets', Biomedicines, vol. 6, no. 1, 32.
Posadas, K, Ankola, A, Yang, Z & Yee, NS-S 2018, 'Tumor molecular profiling for an individualized approach to the treatment of hepatocellular carcinoma: A patient case study', Biomedicines, vol. 6, no. 2, 46.
Yee, NS-S 2018, 'Update in systemic and targeted therapies in gastrointestinal oncology', Biomedicines, vol. 6, no. 1, 34.


Balaban, E, Mangu, PB & Yee, NS-S 2017, 'Locally advanced unresectable pancreatic cancer: American Society of clinical oncology clinical practice guideline summary', Journal of Oncology Practice, vol. 13, no. 4, pp. 265-269.
Yee, NS-S 2017, 'Role of TRPM7 in cancer: Potential as molecular biomarker and therapeutic target', Pharmaceuticals, vol. 10, no. 2, 39.


Ang, C, Miura, JT, Clark Gamblin, T, He, R, Xiu, J, Millis, SZ, Gatalica, Z, Reddy, SK, Yee, NS-S & Abou-Alfa, GK 2016, 'Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options', Journal of Surgical Oncology, vol. 113, no. 1, pp. 55-61.
Yee, NS-S 2016, 'Immunotherapeutic approaches in pancreatic adenocarcinoma: Current status and future perspectives', Current Molecular Pharmacology, vol. 9, no. 3, pp. 231-241.
Balaban, E, Mangu, PB, Khorana, AA, Shah, MA, Mukherjee, S, Crane, CH, Javle, MM, Eads, JR, Allen, P, Ko, AH, Engebretson, A, Herman, JM, Strickler, JH, Benson, AB, Urba, S & Yee, NS-S 2016, 'Locally advanced, unresectable pancreatic cancer: American society of clinical oncology clinical practice guideline', Journal of Clinical Oncology, vol. 34, no. 22, pp. 2654-2667.
Marks, EI & Yee, NS-S 2016, 'Molecular genetics and targeted therapeutics in biliary tract carcinoma', World Journal of Gastroenterology, vol. 22, no. 4, pp. 1335-1347.
Marks, EI & Yee, NS-S 2016, 'Molecular genetics and targeted therapy in hepatocellular carcinoma', Current Cancer Drug Targets, vol. 16, no. 1, pp. 53-70.
Yee, NS-S 2016, TRPM8 Ion Channels as Potential Cancer Biomarker and Target in Pancreatic Cancer. in R Donev (ed.), Advances in Protein Chemistry and Structural Biology. Advances in Protein Chemistry and Structural Biology, vol. 104, Academic Press Inc., pp. 127-155.


Yee, NS-S, Kazi, A, Li, Q, Yang, Z, Berg, A & Yee, RK 2015, 'Aberrant over-expression of TRPM7 ion channels in pancreatic cancer: Required for cancer cell invasion and implicated in tumor growth and metastasis', Biology Open, vol. 4, no. 4, pp. 507-514.
Yee, NS-S 2015, 'Advances in pharmacological treatment of cancer in digestive organs' Current Clinical Pharmacology, vol. 10, no. 4, pp. 254-255.
Yee, NS-S, Kazi, A & Yee, RK 2015, 'Current systemic treatment and emerging therapeutic strategies in pancreatic adenocarcinoma' Current Clinical Pharmacology, vol. 10, no. 4, pp. 256-266.
Fonkoua, LK & Yee, NS-S 2015, 'Immunotherapy in gastric carcinoma: Current status and future perspectives' Clinical Cancer Drugs, vol. 2, no. 2, pp. 91-99.
El-Deiry, WS, Vijayvergia, N, Xiu, J, Scicchitano, A, Lim, B, Yee, NS-S, Harvey, H, Gatalica, Z & Reddy, S 2015, 'Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites', Cancer Biology and Therapy, vol. 16, no. 12, pp. 1726-1737.
Yee, NS-S 2015, 'Roles of TRPM8 ion channels in cancer: Proliferation, survival, and invasion', Cancers, vol. 7, no. 4, A13, pp. 2134-2146.
Wyluda, E & Yee, NS-S 2015, 'Systemic treatment of advanced biliary tract Carcinoma: Emerging roles of targeted therapy and molecular profiling' Clinical Cancer Drugs, vol. 2, no. 2, pp. 80-86.

Clinical Trials Search

Children (age < 18 years)
Adults (age >= 18 years)